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Abstract
Background: Hypertension guidelines recommend the use of thiazide diuretics as first-line therapy for
uncomplicated hypertension, yet diuretics are under-prescribed, and hypertension is frequently inadequately
treated. This qualitative evaluation of provider attitudes follows a randomized controlled trial of a patient activation
strategy in which hypertensive patients received letters and incentives to discuss thiazides with their provider. The
strategy prompted high discussion rates and enhanced thiazide-prescribing rates. Our objective was to interview
providers to understand the effectiveness and acceptability of the intervention from their perspective, as well as
the suitability of patient activation for more widespread guideline implementation.
Methods: Semi-structured phone interviews were conducted with 21 primary care providers. Interviews were
transcribed verbatim and reviewed by the interviewer before being analyzed for content. Interviews were coded,
and relevant themes and specific responses were identified, grouped, and compared.
Results: Of the 21 providers interviewed, 20 (95%) had a positive opinion of the intervention, and 18 of 20 (90%)
thought the strategy was suitable for wider use. In explaining their opinions of the intervention, many providers
discussed a positive effect on treatment, but they more often focused on the process of patient activation itself,
describing how the intervention facilitated discussions by informing patients and making them more pro-active.
Regarding effectiveness, providers suggested the intervention worked like a reminder, highlighted oversights, or
changed their approach to hypertension management. Many providers also explained that the intervention
‘aligned’ patients’ objectives with theirs, or made patients more likely to accept a change in medications. Negative
aspects were mentioned infrequently, but concerns about the use of financial incentives were most common.
Relevant barriers to initiating thiazide treatment included a hesitancy to switch medications if the patient was at or
near goal blood pressure on a different anti-hypertensive.
Conclusions: Patient activation was acceptable to providers as a guideline implementation strategy, with
considerable value placed on the activation process itself. By ‘aligning’ patients’ objectives with those of their
providers, this process also facilitated part of the effectiveness of the intervention. Patient activation shows promise
for wider use as an implementation strategy, and should be tested in other areas of evidence-based medicine.
Trial registration: National Clinical Trial Registry number NCT00265538
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Hypertension affects more than 65 million Americans
and more than 1 million veterans in the Veterans
Administration (VA) [1,2]. Despite recent improvements
in the detection and management of high blood pres-
sure, studies suggest hypertension is still poorly con-
trolled in at least half of VA patients, and likely more in
other settings [1,3-6]. Guidelines suggest thiazide diure-
tics should be given as first-line therapy for uncompli-
cated hypertension and more frequently added to
intensify existing regimens, but thiazides are under-uti-
lized, and identification and appropriate treatment of
patients with hypertension remains inadequate [4-8].
This ‘quality gap’ between evidence-based guidelines and
clinical management of hypertension is not simply a
matter of provider knowledge, but may be more attribu-
table to clinical inertia (i.e., failure to initiate or intensify
therapy when indicated), among other possible factors
[5,9-11].
Provider-targeted interventions that aim to close this
‘quality gap’ in hypertension management have demon-
strated mixed success. Provider education strategies and
audit-and-feedback interventions have had little effect
on management or control [12-14], while computerized
reminders have shown inconsistent results [13,15-17].
However, interventions that incorporate someone other
than the provider (e.g., pharmacist, nurse) into managing
the patient’s hypertension have shown more promise in
supporting guideline-concordant treatment decisions
[18]. The potential role of patients in supporting such
evidence-based care is less explored.
Patient-targeted hypertension interventions have
usually aimed to modify lifestyle risk factors or improve
treatment adherence, and not alter clinical decision-
making. However, patient education has been shown to
enhance the success of some provider- or institution-
ally-targeted hypertension management interventions
when provided in concert [12,13,18], and evidence from
other areas of care suggests providing patients with evi-
dence-based educational materials in clinics may assist
providers in justifying evidence-based treatment deci-
sions [19,20]. The study reported here follows an inter-
vention that aimed to support guideline-concordant
treatment not simply by educating, but by specifically
‘activating’ patients to engage their providers and
request evidence-based therapy.
’Patient activation’ uses the techniques of social mar-
keting and direct-to-consumer (DTC) advertising to
motivate patients to undertake a suggested action [21].
For example, printed materials may be designed to edu-
cate patients with a chronic disease in a manner specifi-
cally focused on motivating exercise or self-management
[22,23]. As a guideline implementation strategy, the
techniques of patient activation have been attempted
only on a limited basis, and while not rigorously evalu-
ated, have thus far shown mixed success [22,24-26]. Our
study follows what was, to our knowledge, the first ran-
domized controlled trial (RCT) of a patient activation
intervention to improve adherence to clinical practice
guidelines. In this trial, patients were provided with tai-
lored information about their blood pressure, including
risks and appropriate therapy, framed as motivation to
pursue a suggested action: discussing the information
with their providers. The intervention was successful in
prompting both high patient-provider discussion rates
and a significant increase in guideline-concordant pre-
scribing [27].
While trial data show increased discussion and pre-
scribing rates, the limitations of these measures and a
paucity of similar research leaves unanswered questions
concerning the process, acceptability and wider suitabil-
ity of the intervention among providers:
1. What factors or elements of the intervention pro-
cess facilitated or prevented changes in prescribing
behavior? Which of these were unique to this interven-
tion, or might be modifiable? Replication and future
adaptation require an understanding of these factors
and their context and consistency within the interven-
tion, and failure to detect differences between imple-
mentation as planned and as practiced reduces the
utility of outcome data [28].
2. How acceptable was the intervention to providers as
stakeholders whose cooperation would be necessary for
broader implementation? Evidence suggests implementa-
tion strategies may not be widely accepted or adopted
by providers who feel their decision latitude is unneces-
sarily diminished [24,29-31], and DTC marketing is con-
troversial [32,33]. What were provider attitudes towards
this intervention that attempted to alter their decision-
making by targeting the patient or ‘consumer’ directly,
and how would they feel if it were implemented more
broadly or applied to other aspects of care?
These questions were addressed through semi-struc-
tured interviews of participating primary care providers,
complemented by patient perspectives reported in a
companion article [34]. We report here results on: how
the intervention created or facilitated changes in the
prescribing behavior of participating providers; what
barriers may have prevented changes in prescribing
behavior; and how acceptable providers found the inter-
vention strategy and its various components. From these
and complementary patient results, we also hope to
inform a broader understanding of the suitability of
patient activation strategies to implement guidelines on
a larger scale, for other therapies, and in alternate
settings.
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The intervention trial
This investigation was conducted following a RCT of a
patient activation intervention to encourage patients
with hypertension to speak with their provider about
starting a thiazide diuretic [27]. All intervention patients
received an individualized letter educating them about
the risks of their hypertension, possible benefits of thia-
zides, and their current anti-hypertensive regimen, while
also suggesting they discuss this information with their
provider. The intervention included three arms: A, B,
and C. Patients in arm A received only the letter, while
patients in arm B also received the offer of twenty dol-
lars for discussing the letter with their provider (regard-
less of whether or not a thiazide was prescribed), as well
as a six-month co-pay reimbursement ($48) if prescribed
a thiazide. Patients in arm C received the letter and
financial incentive, as well as a phone call from a health
educator to remind them of the letter and to answer
any questions about the intervention. All patients were
asked to return a postcard with their provider’ss i g n a -
ture, indicating whether thiazides were discussed and
prescribed. Control patients received usual care. Control
arms were divided into ‘pure controls’ and ‘contami-
nated controls.’ Pure controls were patients of randomly
assigned providers who saw no patients who received
the intervention letter. Contaminated controls were
patients of providers who saw both patients who
received intervention letters (intervention arm A, B, or
C) and those who did not.
Data collection
Telephone interviews were conducted with 21 providers
who participated in the intervention at the Iowa City
and Minneapolis Veterans Affairs Medical Centers
(VAMCs) and four community-based outpatient clinics
(CBOCs). The providers were purposefully sampled by
site. To increase the likelihood they experienced the
intervention, the sample also was limited to the 55 (30
from IA and 25 from MN) providers who had seen at
least four intervention patients. From this sample, provi-
ders were randomly selected and emailed a formal
request letter, followed by a reminder phone call after
two weeks, if necessary. The recruitment process contin-
ued until data redundancy was reached, and approxi-
mately equal numbers were recruited from each site (n
= 10 IA; n = 11 MN). In total, 41 providers were
emailed. Of those, 13 providers did not respond to
emails or phone calls, four declined, and three were
unable to schedule time during the study period (Table
1). The study was approved by the Institutional Review
Boards and Research and Development Committees at
the Iowa City and Minneapolis VAMCs. Written
consent was obtained with permission to record the
interview.
All interviews were performed between May and
S e p t e m b e r2 0 0 8b yt w oo ft h ea u t h o r s( C B D ,H S R ) .
A semi-structured interview guide was used, with open-
ended and probing questions designed to elicit informa-
tion relevant to effectiveness, acceptability, and wider
applicability of the intervention, the main research ques-
tions for the qualitative provider sub-study (See Addi-
tional file 1). The interview guide was revised as new
content was incorporated from previous interviews;
however, the revisions of the interview guide primarily
focused on clarification of questions and adding addi-
tional probes. Interviews lasted 20 to 37 minutes (med-
ian = 30.15) and were documented with a digital voice
recorder. Recordings were transcribed verbatim by a
trained research assistant, and carefully reviewed against
the original recording by the interviewer. Subjects were
identified in transcripts by randomly assigned numbers.
Data analysis
Initial analysis of the first six transcripts was conducted
by three study team members (CBD, HSR, MBW) who
developed a coding template based upon the research
objectives, interview guide, and interview content [35].
The coding template was used to conduct a thematic
content analysis for all interviews, with content codes
assigned to categorize passages [36,37]. The next three
interviews were then independently coded for content
themes to test the codebook. In cases where coders dis-
agreed, differences were discussed until consensus was
reached. Consensus involved the discussion of disagree-
ments among interviewers, including where the coding
of passages should stop and start, passages a coder did
not mark, or the removal of a code from a particular
passage. The consensus process served to increase the
Table 1 Providers response rate by facility type and title
Total Respondents Non-respondents
Total 41 21 (51.22%) 20 (48.78%)
Facility Type
VAMC 11 (26.83%) 10 (24.39%)
CBOC 10 (24.39%) 10 (24.39%)
Provider Type
Physician (MD, DO) 15 (36.58%) 15 (36.58%)
Nurse Practitioner 3 (7.32%) 2 (4.88%)
Physician Assistant 3 (7.32%) 3 (7.32%)
Reason for
non-response
Declined NA 4 (9.75%)
No Response NA 13 (31.71%)
Unable to Schedule NA 3 (7.32%)
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content boundaries of the codes and making coding
more consistent. The final consensus was then entered
into NVivo 8, a software package for qualitative data
management and analysis [38]. The remaining 21 total
transcripts were content coded by the first author
(CBD). Two coders (CB, MW) conducted matrix coding
of passages categorized by thematic content to identify
specific provider responses and the distribution of provi-
der opinions [39]. For example, passages from each pro-
vider that were coded ‘opinion of intervention’ were
independently classified by each coder into the discreet
categories of positive, negative, neutral, or unknown;
disagreements were adjudicated by a third coder (HSR)
who acted as a tiebreaker.
Results
Intervention trial summary
The results from the intervention trial showed that, on
average, 61% of intervention patients discussed thiazides
with their providers [27]. In the three intervention arms,
26% of patients were prescribed a thiazide compared to
only 6.7% of control patients. The addition of financial
incentives and a phone call from a health educator each
showed modest, incremental effects on discussion rates
and subsequent thiazide prescribing.
Below, we focus on the results from the semi-struc-
tured provider interviews, which revealed a number of
opinions and common themes that help to explain this
demonstrated effectiveness and further speak to both the
acceptability and wider applicability of the intervention.
Typical consultations
Of the 21 participating providers, 15 were physicians,
three were physician assistants, and three were nurse
practitioners. All providers indicated they discussed
hypertension and thiazides at the prompting of interven-
tion patients. Conversations were initiated at varying
times in the visit and were of varying length, although
most providers indicated the conversation lasted five
minutes or less. All providers thought most patients
were comfortable initiating the conversation, although
several pointed out that those patients that were not
comfortable likely did not bring in the letter. Only one
provider remembered that a patient specifically
requested to be prescribed a thiazide, and most provi-
ders described their discussions as fitting with one or
both of the following themes:
1. ‘Should I be on this medication?’ Many providers
described discussions in which intervention patients
produced the intervention letter or postcard and
asked if they should be on a thiazide. This was typi-
cally described as a neutral question, although one
provider indicated that one patient was alarmed
there might be an oversight.
2. ‘I was supposed to bring this to you [in order to
get some money].’ Many providers also described
discussions in which intervention patients produced
the intervention letter or postcard as a task they
were instructed to complete. Providers also men-
tioned that some such patients brought up the
incentive as a reward for completing the task.
Influence on prescribing behavior
Most providers (19/21) prescribed thiazides to at least
one patient as a result of the intervention. Their
descriptions of the influence of the intervention can be
broadly categorized into three themes: reinforced their
existing knowledge or prescribing behavior, changed
their approach to hypertension management, and
patient activation itself lowered barriers to thiazide
prescribing.
The intervention reinforced existing knowledge or
prescribing behavior
More than half of interviewed providers suggested the
effect of the intervention was not to change their clinical
approach to hypertension management, but rather to
reinforce their training and current prescribing practice
in a number of ways. Some cited their clinical experi-
ence and understanding of the role of thiazides in sug-
gesting the intervention simply ‘acted like a reminder’ to
consider a thiazide. Others said the intervention brought
their attention to specific patients for whom they would
typically prescribe a thiazide, but were not on one:
’There were some that were oversight...they were
supposed to be on hydrochlorothiazide. They have
no reason not to be on it, and yet they...were not on
it, and your letter brought my attention to it.’
A few providers explained they manage over 1,000
patients, so ‘oversights’ can happen, particularly with
new patients or those co-managed with non-VA provi-
ders. Several providers elaborated on how the interven-
tion brought the patients’ treatment regimens under
new scrutiny:
’With our co-managed patients...I just...tended to
assume, you know, that a thiazide had been tried at
some point, if they’re already on something that I
would’ve picked second, third, or fourth, you know,
as an agent. And, and I’ve, I mean that was, uh, a
big message to me that I can’t assume that.’
Two providers also suggested the intervention pro-
vided previously unknown information that moved
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usually prescribe a thiazide:
’Something that came up a couple times...the letter,
it said ‘on a certain date the blood pressure had
been high,’ and that date had been like on a specialty
care visit, so it was a number that I probably...wasn’t
a w a r eo f . . . b e c a u s em a y b et h e yw e r ef i n et h ed a yI
saw them...and it did change my plan, you know,
after...seeing that.’
The intervention changed the provider’s approach to
hypertension management
Several providers suggested the intervention didn’tj u s t
reinforce existing knowledge or prescribing behavior,
but actually changed their clinical approach to hyperten-
sion management. Some stated the intervention pro-
vided new information about thiazides, or otherwise
changed their view of thiazides as a first-line manage-
ment option:
’It helped certainly, you know, if you come up to me
with a letter and said, ‘hey, this evidence and all
t h a t ,y o uc a nd ot h i sw i t hl e s sc o s ta n de q u a le f f i -
cacy,’ then certainly, you know...that would change
my...practice, behavior, certainly, yeah.’
Others emphasized the intervention brought their
attention to patients who were not simply oversights,
but for whom they may not have considered a thiazide:
’It was almost as if, uh, someone were looking over
my shoulder and saying ‘here, try this.’ It h i n ki n
most cases I agreed and incorporated that as one of
the medications.’
Patient activation itself lowered barriers to thiazide
prescribing
Many providers also described the process of patient
activation as lowering barriers that might otherwise pre-
vent prescribing a thiazide. Some suggested the inter-
vention made patients more receptive to adding or
switching to a thiazide. Particularly with co-managed
patients, several providers said that patients ‘that have
been on...whatever [other] medication for years and
years’ would typically be hesitant to change, especially if
their blood pressure was near or at goal. These provi-
ders suggested the intervention lowered a barrier to
thiazide prescribing by providing patients with informa-
tion and facilitating a discussion:
’Through...the discussion of them even receiving this
invitation in, in the first place, uh, prompted them
to be more willing to start the medicine.’
’Some of them didn’tw a n tt oc h a n g e ,b u t . . . ac o u p l e
of them said, ‘well, let’s, you know, with that infor-
mation, let’s change over’.’
Other providers described the intervention as ‘align-
ing’ patient and provider ‘priorities’:
’One of the most difficult...problems for a practicing,
full-time clinician is trying to stay on schedule, and
if we can help patients to have the same objectives,
align our...priorities, then I think we’ll reach them.
Um, the problem often times is that there’sa n o t h e r
issue, a distracter issue that the patients want to talk
about. They don’tf r e q u e n t l yw a n tt ot a l ka b o u to r
mention a chronic asymptomatic disease. They have
a rash on their elbow and a little ringing in their
ear...and they’ll often consume time just unloading
their frustrations. If, on the other hand, there was an
incentive for them to, uh, focus their energies on the
same objectives WE have, then I think we could
meet those objectives, but we have to stay on time.’
Influence on prescribing behavior beyond the
intervention
Over the course of the intervention, providers who had
patients in the intervention were somewhat more likely
to prescribe a thiazide to their patients in the control
group (i.e., ‘contaminated’ controls) than the providers
who had no intervention patients, but had control
patients (i.e., ‘pure’ controls) (13.2% versus 5.7%;
P=. 0 9 ) .C o r r e s p o n d i n g l y ,1 1o f1 7p r o v i d e r ss t a t e d
they felt the intervention changed the way they pre-
scribed to patients not involved in the study. Most pro-
viders said they were more likely to think of thiazides
first when managing hypertensive patients, and some
suggested it changed the question in their minds from
‘what anti-hypertensive should be used?’ or ‘is the
patient’s hypertension controlled?’ to ‘why is this patient
not on a thiazide?’ Below is a sampling of responses to
the question ‘do you think it [the intervention] changed
the way you prescribed thiazides with other patients?’
’I think it really re-emphasized to me, you know,
going with thiazide diuretics as the first choice.’
’Yeah, it did...believe me. Uh, after I started getting
that letter I started looking more closely at, uh, if I
have a patient with hypertension now. Honestly,
because of your letter I look at it, I look at why is he
not on hydrochlorothiazide.’ (emphasis added).
Providers who felt the intervention did not change their
thiazide prescribing behavior beyond the intervention
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scribed thiazides regularly:
’Id o n ’tt h i n ki tc h a n g e d ,Id o n ’ts e eh o wi tc o u l d
change...because I, uh, I like thiazides...I’m already a
believer.’
Barriers
Providers suggested a number of barriers to the influ-
ence of the intervention that are likely to restrict con-
cordance with hypertension guidelines more generally.
They can be categorized according to three common
themes: guidelines are not universally applicable, reluc-
tance to ‘rock the boat’, and cost and inconvenience.
Guidelines are not universally applicable
Some providers described the influence of the interven-
tion–and guideline concordance more generally–as lim-
ited according to the characteristics of each particular
patient:
’Each patient is individual...and...they need individual
attention. And, uh, sometimes they fall into guide-
lines sometimes they don’t. You know, for example,
I have an eighty-five year old patient, uh, who has a
blood pressure of 170, 180, and I cannot lower that
to 140, patient becomes dizzy and light-headed, I
cannot use the guidelines. So I have to accept higher
blood pressure. You know, I have patients that they
have supine hypertension. Their blood pressure is
200 when they lay down, when they stand up they’re
up to 120. And uh, every time they go to the hospi-
tal, their blood pressure is high. They put them on a
bunch of blood pressure medications. They come
out and they fall down...I cannot use the guideline
for such [a] patient like that.’
Many other providers explained that, especially at the
VA, they often see geriatric patients that are more likely
to have multiple co-morbidities or contra-indications
that make thiazides unsuitable or indicate a greater ben-
efit from another anti-hypertensive:
’You know, my patients are older. They have pros-
tate issues, and they go to bathroom too often, they
have arthritis, they have difficulty to get to the bath-
room...some they had problems with hypokalemia or
renal issues that they were not a candidate for the
medication...and, uh, my patients are diabetic, they
have coronary artery disease, they have, you know,
metabolic syndrome, so I think ACE inhibitors and
ARBs are more selective for them than you know,
just, uh, hydrochlorothiazide.’
Reluctance to ‘rock the boat’
Many providers explained that, while they understand
the benefit of a thiazide, they or often their patients
were nevertheless hesitant to add or switch to a thiazide
if the patient’s blood pressure was already at or near
goal. In the RCT, patients who were not controlled at
the time of their primary care visit were 3.3 times more
likely to be prescribed a thiazide than those who were
controlled:
’I think [it] kind of depended where their blood
pressure was at, you know, if their numbers were
controlled without side effects on the regimen that
they were on, I think there was, you know, a little
bit of uh, um, kind of a sentiment on the part of the
patient and maybe a little reluctance to kind of rock
the boat.’
This was particularly an issue with new or co-mana-
ged patients:
’The...difficulty with being prescribed...are those
patients that [have] been on...another medication for
years by the previous provider or by their private...
physician, and so it’s hard for you to convince them
to change to something different because they say
‘Well I’ve been on this for like, ten years now and
my blood pressure is controlled, why do you want to
change it now?”
Cost and inconvenience
Several providers also mentioned cost and inconveni-
ence to patients as a barrier. Some discussed patients
for whom travel to their VA clinic was lengthy or diffi-
cult, so they didn’t want to be switched if it required an
extra visit for labs. Another provider explained that,
a l t h o u g ht h ec o - p a ya tt h eV Ai saf l a te i g h td o l l a r sf o r
each medication, patients often have many prescriptions,
so the cost of adding one more can be prohibitive.
Based on a similar rationale, another provider described
looking to other anti-hypertensives with a broader range
of indications, thus possibly eliminating the need for
another prescription:
’Diuretics, like thiazide...sometimes I say ‘why I
should make this guy spend eight dollars?’ Let me
just give an ACE and get two things [hypertension
and diabetes treatment] done.’
Acceptability of the intervention
Almost all providers (20/21) had a positive opinion of
the intervention strategy, but many expressed nuanced
opinions, highlighting positive aspects and sometimes
noting reservations.
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When asked their opinion of the intervention, some
providers discussed its positive effect on their approach
to hypertension, but many more focused on the way it
educated patients and facilitated discussion during the
consultation. About one-third stated they had a positive
opinion of the intervention at least in part because it
p r o m p t e dap o s i t i v ec h a n g ei nt h e i rm a n a g e m e n to f
hypertension for some patients. About one-third of pro-
viders also expressed a favorable opinion of the inter-
vention because it made patients more informed about
their hypertension and different therapy options. Finally,
most providers had a positive opinion of the interven-
tion because it promoted among patients a greater inter-
est and involvement in their hypertension management.
These first three themes were often expressed in various
combinations by providers:
’I really liked and, as I said it brought up, it made
me think about things a little differently in some
cases and it brought up great conversations with the
patients.’
’I think it’s good...it makes patients a little more pro-
active about their healthcare...they were interested in
i ta n di tm a d et h e ma c t u a l l y ,y o uk n o w ,t a l kt oy o u
about their blood pressure.’
’It h i n ki t ’s a great idea...for many reasons. The actual
subject matter, of course, is very pressing. Poorly-
controlled hypertension is a well-recognized problem,
and under-utilization of diuretics, and it’sa l s ou m ,a
nice intervention to involve patients and empower
them...it’s...wonderful to get the patients involved
directly in their care, and uh, inform them of the
goals and the methods of achieving those goals.’
A few providers also explained that a necessary condi-
tion for the acceptability of this intervention was the
‘well-established profile’ and sometimes the ‘cost-effec-
tiveness’ of thiazide diuretics:
’For hydrochlorothiazide, it is good...an enduring
medication, a good medication...you just need the
doctors to be aware of the effectiveness. But if you
start promoting...all these fancy new medications
[with this type of intervention]...I wouldn’te n c o u -
rage it.’
Negatives/reservations
Despite their overall receptivity to the patient activation
approach, a number of providers expressed some con-
cern or reservations about certain aspects of the inter-
vention, a majority of which were focused on the use of
incentives. Most reservations were expressed in the con-
text of a positive opinion of the overall intervention
strategy, as only one provider articulated a negative view
of the intervention in general. Almost all the negatives/
reservations expressed fit into two themes, with a third
theme mentioned.
Financial incentives can create a conflict of interest
Four providers suggested the use of financial incentives
created conflicting motivations for patients. A couple
expressed this as a normative statement, suggesting sim-
ply that patients should be motivated not by money, but
by what is good for their health; interestingly, a similar
opinion was expressed by patients involved in the study.
Two other providers suggested that the motivation cre-
ated by the incentives could push patients to seek out a
diuretic regardless of its suitability for them, thus com-
promising some of the provider’s autonomy: ‘If they are
more interested in getting [the incentive], that kind of
put pressure on us not to say no.’
A couple of providers also suggested that incentives
may not be cost-effective, and one was concerned that
patients might think the VA had an ‘alternative motive’
for offering an incentive because it is not typical practice
at the VA.
However, it is worth noting that 13 of 17 providers
asked actually had a positive or neutral view of the use
of incentives. Most of these providers explained that if
the incentives enhanced the patients’ interest in their
hypertension care, then they were fine with their inclu-
sion, saying ‘if it’sg o i n gt ow o r k ,I ’ma l lf o ri t . ’ Also,
most providers said some patients seemed motivated by
the $20 incentive to have a discussion, while providers
felt few patients seemed motivated by the six-month co-
pay reimbursement or pushed for a prescription because
of it.
The intervention might undermine patient trust Two
providers expressed a concern that the intervention
might suggest providers are giving inadequate care:
’As a physician...I often have a good reason for the
decisions I make, and...I worry about it giving the
message to, uh, the patient that ‘your doctor should
be doing this, and your doctor is not’.’
This concern was hypothetical for one provider, who
also had a negative overall view of the intervention
strategy. However, the other provider that expressed the
concern did report a patient coming in with the impres-
sion that he received the letter because his provider had
not prescribed the correct medication. This provider
reported that the patient’sc o n c e r nw a sa p p e a s e di nd i s -
cussing the intervention further:
’I explained the situation to him...I told him why I
didn’t put him on hydrochlorothiazide, and why I
would not put him on hydrochlorothiazide, and he
was happy.’
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vention, but was concerned that trust might still be
undermined if a patient was not so easily appeased. It is
worth noting that several other providers specifically
volunteered that they didn’t feel the intervention
prompted any distrust:
’I did not have any...challenging interactions in the
sense that somebody was either questioning my
judgment, or upset, or thought there was an over-
sight...it was a very non-threatening conversation...
and there wasn’t any distrust, so they pretty well just
believed my explanation if I said ‘I don’t think this is
appropriate.’ And they also, I didn’t get the feeling
of, you know, having them lose confidence in me if I
said ‘Yup...let’s do it. Thanks for bring it to my
attention.’
The wrong patients might be ‘activated’ Similar to the
previously described prescribing barrier–thiazides may
not be a universally acceptable therapy–a couple of pro-
viders were also concerned that the intervention strategy
m i g h tb et a r g e t e da tp a t i e n t st h a ts h o u l dn o tb eo nt h e
promoted therapy. For example, one cautioned against
targeting geriatric patients for thiazides, explaining that
too often there are too many complications, and another
explained if clinic rather than home blood pressure
readings are used to identify target patients, it may cre-
ate confusion in patients with controlled hypertension.
Broader acceptability
In all, 18 of 20 providers asked had a positive opinion
about using patient activation strategies on a broader
basis for implementing hypertension or other therapy
guidelines:
’Iw o u l d n ’t mind seeing either more studies like this
or even just having that be part of our practice of
care...where the patient’s getting letters...hyperten-
sion is a great idea or cholesterol would be another.’
As with explaining their opinions of the intervention
itself, providers most often discussed how the patient
activation strategy informs patients and facilitates dis-
cussions:
Interviewer: ‘What do you think in general about
promoting things such as new guideline therapies
through patient-initiated interventions...taking infor-
mation to the patient and having them bring it in?’
Provider one: ‘I think that is actually a good idea...you
can educate patient...and again...it make the job of
physician easier, you know, when they come to the
doctor they said, ‘Is this right for me?’ So then you
don’t have to start up the whole conversation again.’
Provider two: ‘I think that’s really kind of forming an
alliance with your patient as, as you together deter-
mine what the best therapy is, so I don’t, I don’ts e e
any problem with that. There’s probably much to be
gained.’
Provider three: ‘I think that...would be...a wonderful
idea, I think like I said earlier that, um, maybe
prompting patients this way, uh, might...make them
more interested and proactive with their healthcare.’
In explaining their opinion, other providers re-iterated
the strategy had prompted useful changes in their man-
agement of some patients, and a few mentioned that
they thought the strategy would prove cost-effective.
Two providers had negative or ambivalent views about
using patient activation strategies on a larger scale. One
supported broader use of the intervention to promote
thiazides, but was hesitant to endorse its use for any
other therapy, particularly for medications that were not
as ‘well-established’ as thiazides. The other expressed
concern that if the strategy was used for too many
therapies, providers would quickly become saturated
and the strategy would become ineffective.
Sources that inform prescribing behavior
Through a number of questions providers listed sources
that inform their prescribing behavior (Table 2). Since
the intervention was focused on influencing their pre-
scribing behavior, the list of sources offered insight into
the providers’ perceptions of other approaches to pro-
moting evidence-based therapy. Most providers men-
tioned two or three sources, and few mentioned more
than three. Most often mentioned was the scientific lit-
erature, although most of the nine providers that
b r o u g h ti tu pe x p l a i n e dt h e yd o n ’th a v et i m et ol o o ka t
the literature regularly, or only look at a specific journal
or two. Seven providers mentioned electronic databases,
and other sources were more varied and disparate, each
mentioned by five or fewer providers.
Table 2 Free-listed sources that inform provider
prescribing behavior.*
Journals (9) Peers (informally) (4)
Electronic Databases (7) CME Lectures (3)
Websites (5) Pharmacists (3)
Board Certification (4) Residency/Fellowship (3)
Guideline Database (4) Clinical Experience (3)
Opinion Leaders (3) Institutional Memos/Directives (2)
Clinical Experience (3) Grand Rounds (2)
Meetings (2) Email Notifications (2)
Pharma Reps (2) Medical School (1)
*Numbers in parentheses indicate the number of providers who mentioned
the source
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This patient activation intervention was not only effec-
tive at changing provider prescribing behavior [27], but
was also acceptable to providers, most of whom had a
positive opinion of both the intervention and the wider
use of patient activation as an implementation strategy.
In describing its efficacy, most providers focused first on
the process of patient activation itself, describing how
the intervention facilitated discussions by informing
patients and making them more pro-active. Some
described the effects of the intervention as similar to
several other implementation strategies, acting as a
reminder to consider a thiazide, flagging patients that
were ‘oversights,’ or even prompting a re-evaluation of
the evidence and rationale for prescribing thiazides as
first-line therapy. Many also described the intervention
as facilitating change in a manner more unique to
patient activation, by ‘empowering’ patients and ‘align-
ing’ the ‘priorities’ of the patient and provider, with the
consequence of making consultations more directed and
efficient, or making patients more willing to accept a
change in medications.
Uncontrolled hypertension may have been particularly
well suited to this patient activation intervention and
the ways providers described the intervention as facili-
tating change. Few providers indicated that the interven-
tion provided them with any new information about
thiazides, supporting previous evidence that the gap
between evidence and practice in the case of hyperten-
sion management is more a matter of clinical inertia
rather than provider knowledge [4,5,10,11]. These stu-
dies suggest that two primary contributors to clinical
inertia–or failure to initiate or intensify therapy when
indicated–may be clinical uncertainty and competing
demands. It is possible that this intervention helped to
overcome clinical uncertainty by providing a sort of
confirmation that treatment would be appropriate, parti-
cularly for those cases in which providers described the
intervention acting as a ‘reminder’ or highlighting ‘over-
sights.’ The targeted, personalized information contained
in the letter, the presentation of the letter in clinical
appointments, and the source of the letter could all
have played a role in reinforcing for providers the cer-
tainty of the indication for treatment with thiazides.
Further, providers’ description of the intervention as
‘aligning’ patient and provider ‘priorities’ suggests the
intervention reduced competing demands within the
consultation, focusing the discussion on an asympto-
matic condition that may otherwise be superseded by
more acute or symptomatic concerns.
At the same time, some potential concerns about the
process and acceptability of this intervention surround
the patient-initiated approach to initiating changes in
provider behavior. Patient-initiated demand for services
often takes the form of specific requests, and such
requests have been found to have a significant effect on
providers’ clinical decisions [40-42]. However, requests
can consume limited consultation time and be perceived
as demanding by physicians, while failure to fulfill a
request, even when the requested service is not indi-
cated, can threaten patient satisfaction and trust [40-42].
Of particular concern have been requests for potentially
inappropriate prescribing or other improper or unneces-
sary care generated by the advertising techniques
adopted for patient activation [33,43-50].
Interestingly, however, only one provider interviewed
responded that a patient had specifically requested a
thiazide prescription, and the vast majority instead
described patients as initiating the discussion with a
question about thiazides or presenting the intervention
letter simply as a task they were to complete. Perhaps
correspondingly, provider responses suggest there was
little if any pressure to prescribe or sense of dissatisfac-
tion or mistrust from patients if the provider decided a
thiazide was not appropriate. A study of patient perspec-
tives of the intervention found patients described their
interactions with their providers in similar ways [34].
Given the efficacy of the intervention, it seems the letter
and prompt for discussion preserved some of the posi-
tive influence that can be generated by a patient request
without the pressure that could be viewed as negative.
This suggests that, while the intervention was intended
to create a specific demand for evidence-based therapy,
there may be value in designing interventions that focus
more on generating specific discussions rather than
patient demand.
This idea is supported further by providers’ comments
on the value and acceptability of the intervention. Some
did point out that it reinforced or broadened their utili-
zation of thiazides as first-line therapy, but providers
focused much more on the process, describing how they
appreciated that the intervention facilitated discussions
by informing patients and making them more pro-active
while focusing the consultation by ‘aligning’ the priori-
ties of the patient and provider. This emphasis on the
interface itself suggests the effects or outcomes of this
intervention are not limited to prescribing behavior, but
rather include the provider-patient interaction generated
by patient activation. Thus, even if patients were not
prescribed for whatever reason, providers still valued the
information patients received, the interest generated,
and the discussions that were prompted.
This sort of informed patient participation has been
increasingly advocated [50-56], and improved patient-
provider concordance–or decision-making based on
shared information and negotiation–may improve
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[48,57]. Though providers emphasized the value of the
discussions the intervention generated, the degree to
which the prescribing decisions were shared in this case
is not fully apparent from the interview data. The results
do suggest that the satisfaction of providers with the
discussions generated in this intervention is related at
least in part to the selection of appropriately indicated
patients and the focus provided by the intervention
letter. Such targeted patient activation may prove
more widely useful in both generating informed discus-
sion and targeting it to improve patient-provider
concordance.
While providers valued patient participation in this
intervention, they did not look to patients as a source
for new evidence to inform their prescribing behavior,
as the absence of ‘patients’ from the free-listed sources
in Table 2 illustrates. In describing the influence on
their behavior, providers rather suggested the patients
served as a reminder or reinforcement, while occasion-
ally the letter itself provided new information or evi-
d e n c ec o n s i d e r e db yp r o v i d e r s .H o w e v e r ,t h el i s to f
sources in Table 2 also illustrates that, even among pro-
viders in the same structured health system, sources
that inform prescribing are disparate and variable. Yet,
patients are one commonality with which all providers
will interact, and through whom reinforcement of infor-
mation can be directed. In combination with many pro-
viders’ explanation that this intervention was
particularly acceptable because thiazides are so well-
established, this suggests patient activation as an imple-
mentation strategy is perhaps best suited for therapies
for which the evidence-base is strong and widely disse-
minated, but which are nonetheless frequently over-
looked, such as treatments for other common, chronic
diseases or certain types of preventive care.
Barriers
Several barriers were discussed by providers, the most
frequent of which was particular characteristics of
patients that may make them unsuitable for guideline
therapy. The reasons given for this, such as age, co-mor-
bidities, or contra-indications, are common and typically
appropriate reasons for non-adherence to other guide-
lines [58,59]. In the case of hypertension, guidelines sug-
gest thiazide diuretics as first-line therapy for
uncomplicated hypertension, so it seems the autonomy
of the provider to decide which patients could be classi-
fied as such was preserved.
Negatives
Negatives were mostly expressed in the context of posi-
tive overall opinions of patient activation as an imple-
mentation strategy. Financial incentives were mentioned
most often, though a majority of providers did have a
positive or neutral opinion of using incentives. Interest-
ingly, however, incentives may not even be necessary in
this type of intervention. Discussion rates were high
regardless of incentives, which showed only a modest
effect.
While a few providers were concerned the interven-
tion might undermine patients’ trust in the quality of
care they provide, only one reported a patient that was
explicit about feeling this way, and this patient’s concern
was quickly allayed. This theme was only infrequently
mentioned by patients as well [34]. Most providers
emphasized that they welcomed the questions and dis-
cussion that were prompted, and several pointed out
that patients were not accusatory or threatening in any
way. Concerns about ‘activating’ the wrong patients
reinforces that patients targeted for activation in future
interventions should be carefully screened. However,
with the autonomy of the providers seemingly intact in
the intervention, they reported very few problems in let-
ting patients know if they were not suitable for a thia-
zide diuretic.
Limitations
There are several limitations to the study. First, its gen-
eralizability is limited due to the focus on VA providers
from two VAMCs, as well as the small sample size.
However, the qualitative design allowed for an informa-
tion-rich analysis of provider perspectives of a patient
activation strategy that could be expanded in future stu-
dies. Second, it relies on providers that agreed to be
interviewed, and it is possible that such providers had
more positive views of the intervention. Further, some
providers may not have fully understood or remembered
the intervention. The phone interviews were often con-
ducted several months after providers saw patients, and
several needed to be reminded about the details of the
intervention. However, efforts were made during inter-
views to ensure providers were clear on the details and
purpose of the intervention before giving their opinions,
and most providers understood the intervention and
remembered their consultations with little or no
prompting or clarification. Finally, social desirability bias
may have influenced both the providers and the inter-
viewers. Providers may have reported that they under-
stood and were guided by hypertension guidelines even
if it is not clear they were. On the other hand, a social
desirability bias may have hindered interviewers from
explicitly asking providers why they were not prescribing
thiaizides (even though they stated that they understood
the guidelines). Such influences could have interfered
with gaining a better understanding of why the discus-
sion with patients prompted such an increase in
prescribing.
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Patient activation was not only effective at implementing
thiazide diuretics, but provider interviews suggested it
was also acceptable in the context of this intervention,
and could be similarly acceptable if utilized for broader
implementation efforts. The effects on prescribing beha-
vior were facilitated in some ways unique to patient
activation, and providers did report valuing the changes
in patient care prompted by the intervention, but they
focused much more on the value of patient activation
itself and the interest and discussions it generated. This
emphasis suggests that the benefit of the intervention
was not limited to its effects on prescribing behavior,
but rather included facilitating a more mutually
informed and focused clinical encounter.
Patient activation shows potential as an implementa-
tion strategy that may not only reinforce existing evi-
dence or guidelines, but may also initiate and guide
patient-provider discussions with the potential of ‘align-
ing’ the priorities of patients and providers. Patient acti-
vation should be tested as in implementation strategy in
other areas of evidence-based medicine.
Additional file 1: Summative Evaluation for the VA Project to
Implement Diuretics (VAPID). Interview guide developed to conduct
semi-structured interviews with providers after completion of the
intervention.
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